A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response
- 14 September 2020
- journal article
- research article
- Published by Springer Nature in Nature Cancer
- Vol. 1 (11) , 1054-1065
Abstract
Antibody-mediated modulation of major histocompatibility complex (MHC) molecules, or MHC class I-like molecules, could constitute an effective immunotherapeutic approach. We describe how single-domain antibodies (VHH), specific for the human MHC class I-like molecule CD1d, can modulate the function of CD1d-restricted T cells and how one VHH (1D12) specifically induced strong type I natural killer T (NKT) cell activation. The crystal structure of the VHH1D12-CD1d(α-GalCer)-NKT T-cell receptor (TCR) complex revealed that VHH1D12 simultaneously contacted CD1d and the type I NKT TCR, thereby stabilizing this interaction through intrinsic bispecificity. This led to greatly enhanced type I NKT cell-mediated antitumor activity in in vitro, including multiple myeloma and acute myeloid leukemia patient-derived bone marrow samples, and in vivo models. Our findings underscore the versatility of VHH molecules in targeting composite epitopes, in this case consisting of a complexed monomorphic antigen-presenting molecule and an invariant TCR, and represent a generalizable antitumor approach.Keywords
This publication has 47 references indexed in Scilit:
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune DiseasesCell, 2020
- Cancer NeoantigensAnnual Review of Immunology, 2019
- Unconventional T Cell Targets for Cancer ImmunotherapyImmunity, 2018
- Natural Killer T Cells in Cancer ImmunotherapyFrontiers in Immunology, 2017
- The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A ReviewJournal of Immunology Research, 2016
- Blocking MHC class II on human endothelium mitigates acute rejectionJCI Insight, 2016
- TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicityCurrent Opinion in Immunology, 2015
- T Cell Antigen Receptor Recognition of Antigen-Presenting MoleculesAnnual Review of Immunology, 2015
- Recognition of CD1d-restricted antigens by natural killer T cellsNature Reviews Immunology, 2012
- Requirements for CD1d Recognition by Human Invariant Vα24+ CD4−CD8− T CellsJournal of Experimental Medicine, 1997